Ena Segota

  • Citations Per Year
Learn More
BACKGROUND Capecitabine is an orally administered fluoropyrimidine that is converted to 5-fluorouracil by thymidine phosphorylase. In view of the recognized synergism of fluoropyrimidines with interferon-alpha (IFNalpha), a Phase II study to characterize the toxicity and efficacy of the combination of capecitabine and rHuIFNalpha-2a for the treatment of(More)
Toxic chemotherapeutic agents are slowly being supplemented by a new generation of drugs that recognize specific targets in or on cancer cells. Although these molecular and genetic approaches are in their infancy, they hold the promise of more effective therapies with markedly fewer side effects. Several targeted agents are already approved by the US Food(More)
6039 Background: Randomized clinical trials (RCT) that stop earlier than planned because of apparent benefit often receive great attention. However, how often these early results get confirmed by other subsequent meta-analysis/randomized studies, and how often results get included in clinical guidelines is not known. We conducted systematic review of(More)
Individuals carrying pathogenic mutations in the BRCA1 and BRCA2 genes have a high lifetime risk of breast cancer. BRCA1 and BRCA2 are involved in DNA double-strand break repair, DNA alterations that can be caused by exposure to reactive oxygen species, a main source of which are mitochondria. Mitochondrial genome variations affect electron transport chain(More)
8229 Background: Several randomized studies evaluating pegfilgrastim and filgrastim have shown no difference in ANC patterns in cycle 2 compared to cycle 1 of chemotherapy. We have observed an interesting ANC pattern in a phase II clinical study evaluating the safety and efficacy of accelerated dose- intensified neoadjuvant epirubicin with pegfilgrastim(More)
4631 Background: The impact of OM on survival in patients with RCC is controversial. In several recent database studies OM have been reported to have a negative effect on survival (Negrier, Ann Oncol. 2002; 13:1460, Atzpoodien, B J Cancer. 2003; 88:348), while in others it has been reported to have no effect (Motzer, J Clin Oncol. 2002; 20:289). METHODS(More)
  • 1